nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
|
Yasuda, Hiroyuki |
|
|
162 |
C |
p. 140-146 |
artikel |
2 |
CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer
|
Liu, Qian |
|
|
162 |
C |
p. 194-202 |
artikel |
3 |
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients
|
Demedts, Ingel |
|
|
162 |
C |
p. 90-95 |
artikel |
4 |
Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
|
Liang, Qi |
|
|
162 |
C |
p. 86-89 |
artikel |
5 |
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
|
Bazhenova, Lyudmila |
|
|
162 |
C |
p. 154-161 |
artikel |
6 |
Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy – A path forward?
|
Filippi, Andrea R. |
|
|
162 |
C |
p. 203-206 |
artikel |
7 |
Contents
|
|
|
|
162 |
C |
p. iv-vi |
artikel |
8 |
Corrigendum to “Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions” [Lung Cancer 159 (2021) 66–73]
|
Mondaca, Sebastian |
|
|
162 |
C |
p. 210 |
artikel |
9 |
Corrigendum to “eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer” [Lung Cancer 160 (2021) 36–43]
|
Buma, Alessandra I.G. |
|
|
162 |
C |
p. 211 |
artikel |
10 |
Cryobiopsy as a reliable technique for the preoperative identification of micropapillary/solid components in early-stage lung adenocarcinoma
|
Suzuki, Mikito |
|
|
162 |
C |
p. 147-153 |
artikel |
11 |
Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations
|
Wu, Yifen |
|
|
162 |
C |
p. 207-209 |
artikel |
12 |
Editorial Board
|
|
|
|
162 |
C |
p. iii |
artikel |
13 |
Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II–IIIA (8th edition TNM classification) primary lung cancer after curative surgery
|
Isaka, Tetsuya |
|
|
162 |
C |
p. 128-134 |
artikel |
14 |
Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39)
|
Mody, Gita N. |
|
|
162 |
C |
p. 1-8 |
artikel |
15 |
Immune checkpoint inhibitor therapy for malignant pleural mesothelioma
|
Nowak, Anna K |
|
|
162 |
C |
p. 162-168 |
artikel |
16 |
Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis
|
Matsumoto, Kinnosuke |
|
|
162 |
C |
p. 175-184 |
artikel |
17 |
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
|
Hamada, Akira |
|
|
162 |
C |
p. 79-85 |
artikel |
18 |
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer
|
Li, Min |
|
|
162 |
C |
p. 16-22 |
artikel |
19 |
Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
|
Aggarwal, Charu |
|
|
162 |
C |
p. 42-53 |
artikel |
20 |
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers
|
Gutierrez, Martin |
|
|
162 |
C |
p. 23-28 |
artikel |
21 |
Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis
|
Fjaellegaard, Katrine |
|
|
162 |
C |
p. 106-118 |
artikel |
22 |
Propensity score matched analysis for the role of surgery in stage Ⅲ small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital
|
Gao, Lin |
|
|
162 |
C |
p. 54-60 |
artikel |
23 |
Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?
|
Crockett, Cathryn |
|
|
162 |
C |
p. 96-105 |
artikel |
24 |
Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study
|
Pompili, Cecilia |
|
|
162 |
C |
p. 71-78 |
artikel |
25 |
Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
|
Kwok, Wang Chun |
|
|
162 |
C |
p. 169-174 |
artikel |
26 |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
|
Popat, Sanjay |
|
|
162 |
C |
p. 9-15 |
artikel |
27 |
The effect of home-based preoperative pulmonary rehabilitation before lung resection: A retrospective cohort study
|
Saito, Takashi |
|
|
162 |
C |
p. 135-139 |
artikel |
28 |
The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
|
Schakenraad, Alexandra |
|
|
162 |
C |
p. 36-41 |
artikel |
29 |
Thoracic surgery improved overall survival in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment
|
Chien, Yu-Ning |
|
|
162 |
C |
p. 29-35 |
artikel |
30 |
Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative
|
Baas, Paul |
|
|
162 |
C |
p. 185-193 |
artikel |
31 |
Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort
|
Girard, Nicolas |
|
|
162 |
C |
p. 119-127 |
artikel |
32 |
Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands
|
Evers, Jelle |
|
|
162 |
C |
p. 61-70 |
artikel |